Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the data actually delivered what investors spent months betting on.